JP2024538573A5 - - Google Patents

Info

Publication number
JP2024538573A5
JP2024538573A5 JP2024518745A JP2024518745A JP2024538573A5 JP 2024538573 A5 JP2024538573 A5 JP 2024538573A5 JP 2024518745 A JP2024518745 A JP 2024518745A JP 2024518745 A JP2024518745 A JP 2024518745A JP 2024538573 A5 JP2024538573 A5 JP 2024538573A5
Authority
JP
Japan
Prior art keywords
cancer
antibody
region
fragment
immunostimulant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024518745A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538573A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/077270 external-priority patent/WO2023052581A1/en
Publication of JP2024538573A publication Critical patent/JP2024538573A/ja
Publication of JP2024538573A5 publication Critical patent/JP2024538573A5/ja
Pending legal-status Critical Current

Links

JP2024518745A 2021-10-01 2022-09-30 免疫刺激剤としてのアゴニスト性cd40抗体 Pending JP2024538573A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21200496.4 2021-10-01
EP21200496 2021-10-01
PCT/EP2022/077270 WO2023052581A1 (en) 2021-10-01 2022-09-30 Agonistic cd40 antibodies as immune stimulatory agents

Publications (2)

Publication Number Publication Date
JP2024538573A JP2024538573A (ja) 2024-10-23
JP2024538573A5 true JP2024538573A5 (cg-RX-API-DMAC7.html) 2025-10-07

Family

ID=78078007

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024518745A Pending JP2024538573A (ja) 2021-10-01 2022-09-30 免疫刺激剤としてのアゴニスト性cd40抗体

Country Status (7)

Country Link
US (1) US20240392026A1 (cg-RX-API-DMAC7.html)
EP (1) EP4408537A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024538573A (cg-RX-API-DMAC7.html)
CN (1) CN118139886A (cg-RX-API-DMAC7.html)
AU (1) AU2022358474A1 (cg-RX-API-DMAC7.html)
CA (1) CA3232917A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023052581A1 (cg-RX-API-DMAC7.html)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2019057792A1 (en) * 2017-09-19 2019-03-28 Mab Discovery Gmbh CD40 ANTIBODY AGONISTS

Similar Documents

Publication Publication Date Title
JP7685095B2 (ja) 多重特異性抗体とその作製及び使用方法
JP7356970B2 (ja) 多重特異性抗体とその作製及び使用方法
FI3932951T3 (fi) Menetelmiä ihosyövän hoitamiseksi antamalla PD-1-inhibiittoria
JP2021511058A5 (cg-RX-API-DMAC7.html)
IL272770B1 (en) CD40 agonist antibodies
FI3810281T3 (fi) Menetelmiä syövän hoitamiseksi bispesifisillä anti-CD3XMUC16-vasta-aineilla ja anti-PD-1-vasta-aineilla
AU2016281641A1 (en) Novel PD-1 immune modulating agents
JP2019515008A5 (cg-RX-API-DMAC7.html)
JP2021528423A5 (cg-RX-API-DMAC7.html)
FI3736292T3 (fi) CD3-vasta-aineita ja käyttömenetelmiä
IL313468A (en) Multi-specific antibodies and methods of making and using thereof
TW201902514A (zh) Pd-1抗體與vegf配體或vegf受體抑制劑聯合在製備治療腫瘤的藥物中的用途
FI3452513T3 (fi) Humanisoituja anti-il-1r3-vasta-aineita
JP2024520666A5 (cg-RX-API-DMAC7.html)
JP2022545741A5 (cg-RX-API-DMAC7.html)
JP2020515577A5 (cg-RX-API-DMAC7.html)
JP2024016024A5 (cg-RX-API-DMAC7.html)
JP2023519807A5 (cg-RX-API-DMAC7.html)
JP2024527576A5 (cg-RX-API-DMAC7.html)
CN117693350A (zh) 用于治疗癌症的检查点抑制剂与溶瘤病毒的组合
NZ761899B2 (en) Agonistic cd40 antibodies
RU2022118282A (ru) Новые полипептиды
NZ781933B2 (en) Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
RU2024117128A (ru) СПОСОБЫ ЛЕЧЕНИЯ РАКА ПОСРЕДСТВОМ БИСПЕЦИФИЧЕСКИХ АНТИТЕЛ К CD3 x MUC16 И АНТИТЕЛ К CTLA-4
NZ781933A (en) Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer